Diversified Trust Co Makes New Investment in DaVita Inc. $DVA

Diversified Trust Co purchased a new stake in DaVita Inc. (NYSE:DVA) in the 1st quarter, HoldingsChannel reports. The fund purchased 7,502 shares of the company’s stock, valued at approximately $1,153,000.

A number of other hedge funds also recently made changes to their positions in the stock. Hsbc Holdings PLC lifted its position in shares of DaVita by 71.7% in the 4th quarter. Hsbc Holdings PLC now owns 133,080 shares of the company’s stock worth $15,110,000 after purchasing an additional 55,553 shares during the period. Rockefeller Capital Management L.P. increased its position in shares of DaVita by 26.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,049 shares of the company’s stock worth $119,000 after buying an additional 221 shares during the period. Corient Private Wealth LLC raised its stake in DaVita by 22.5% during the fourth quarter. Corient Private Wealth LLC now owns 27,559 shares of the company’s stock worth $3,131,000 after buying an additional 5,069 shares during the last quarter. Sankala Group LLC bought a new position in DaVita during the fourth quarter worth $39,000. Finally, Virtu Financial LLC acquired a new position in DaVita in the fourth quarter valued at $451,000. 90.12% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the transaction, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is currently owned by corporate insiders.

DaVita Trading Up 0.7%

NYSE:DVA opened at $211.11 on Wednesday. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $215.33. The stock has a market capitalization of $13.55 billion, a price-to-earnings ratio of 19.58, a PEG ratio of 0.69 and a beta of 0.91. The firm has a fifty day simple moving average of $184.62 and a two-hundred day simple moving average of $150.69.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. The firm had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts predict that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on DVA shares. TD Cowen increased their price target on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a report on Monday, May 11th. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Truist Financial raised their target price on DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research note on Friday, May 8th. Finally, Barclays lifted their target price on DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, DaVita has a consensus rating of “Hold” and an average price target of $199.17.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.